Bone Biologics Corporation: Business Overview, Financials & Competitive Analysis

Bone Biologics Corporation Overview

Bone Biologics Corporation is a developer of orthobiologic products for spine fusion markets listed on NASDAQ under ticker BBLG. The company is advancing a first-in-human pilot clinical study of NB1, which combines recombinant human NELL-1 protein with demineralized bone matrix for use in spinal fusion procedures. The company is executing a focused clinical strategy while maintaining capital discipline in a competitive regenerative medicine space.

Strategic Profile

Bone Biologics' proprietary platform technology is NELL-1, a recombinant human protein growth factor essential for normal bone development. In May 2026, the company extended its rhNELL-1 protein shelf life to 29 months, supporting manufacturing flexibility and supply chain planning as the program progresses toward a potential future pivotal study. As of July 2026, the company completed a private placement generating approximately $3.0 million in gross proceeds, with warrants that could provide up to $6.0 million in additional proceeds.

Competitive Landscape

Spine fusion is characterized as an underserved market. Bone Biologics competes in the orthobiologics and bone regeneration space with companies offering alternative bone graft substitutes, demineralized bone matrices, and synthetic scaffolds for spinal fusion applications. Direct competitors include established orthobiologic players offering both allograft and synthetic alternatives, though Bone Biologics' NELL-1 protein represents a differentiated biologic approach.

Industry Context

Bone Biologics Corporation operates in Orthopedic Devices.

Key facts

Founded: 2004 · Headquarters: Burlington, Massachusetts, US · Employees: 10-20 estimated · Revenue: No current revenue; pre-commercial clinical-stage · Market cap: $1.5M